BEYOND AIR INC. - COMMON STOCK

Beyond Air® Secures up to $40 Million Debt Financing

15 Jun 2023 15:10:00 By Nasdaq GlobeNewswire

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

15 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

16 May 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

19 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

23 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting

14 Mar 2023 15:35:00 By Nasdaq GlobeNewswire

Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023

22 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023

09 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer

30 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board

24 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

17 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

13 Dec 2022 08:25:14 By Nasdaq GlobeNewswire

Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference

17 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

08 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

24 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

20 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022

17 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting

05 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

03 Oct 2022 06:30:00 By Nasdaq GlobeNewswire